Cbl-b-IN-9

• Description :

  Cbl-b-IN-9 (Compound 300) is a casitas B-lineage lymphoma-b (Cbl-b) and c-Cbl inhibitor with IC50s of 5.6 nM and 4.7 nM, respectively[1].

• UNSPSC :

  12352005

• Target :

  E1/E2/E3 Enzyme

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cbl-b-in-9.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C1C2=C(CN1C3=CC(C4(CC5=NN=CN5C)COC4)=CC(C6CC6)=N3)C(C(F)(F)F)=CC(CNC7(CCC7)C)=C2

• Molecular Formula :

  C30H33F3N6O2

• Molecular Weight :

  566.62

• References & Citations :

  [1]Jun Liang, et al. Lactams as cbl-b inhibitors. Patent WO2022169997A1.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2815223-41-5]